A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
Status:
NOT_YET_RECRUITING
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with Attention Deficit Hyperactivity Disorder（ADHD）.